Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2014 Results
Date:8/7/2014

well as in patients with Smith-Magenis syndrome.

The VLY-686, NK1 antagonist, Phase 2 study in chronic pruritus is ongoing and results are expected in mid-2015.  

2014 FINANCIAL GUIDANCETotal 2014 operating expenses are expected to be between $110.0 and $120.0 million.  This includes intangible asset amortization expense of $2.3 million and $6.0 to $8.0 million of non-cash stock based compensation.

Full HETLIOZ® Prescribing Information can be found at: www.hetlioz.com

CONFERENCE CALLVanda has scheduled a conference call for today, Thursday, August 7, 2014, at 10:00 AM ET.  During the call, Vanda's management will discuss the second quarter 2014 financial results and other corporate activities.  Investors can call 1-800-708-4540 (domestic) and 1-847-619-6397 (international) and use passcode 37729521.  A replay of the call will be available beginning Thursday, August 7, 2014 at 12:30 PM ET and will be accessible until Thursday, August 14, 2014, at 11:59 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The access number is 37729521.

The conference call will be broadcast simultaneously on Vanda's website, www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.

CAUTIONARY N
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
2. Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
3. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
4. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
5. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
6. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
7. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
8. Vanda Pharmaceuticals, Inc. Sued by Investor
9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2, 2014   Softworld, Inc. announced today the ... solely focused on the specific needs of pharmaceutical, biotech, ... has already been highly successful in the clinical domain, ... to support the quality, regulatory, and validation space. ... combination of the current Biometric team and the newly ...
(Date:10/2/2014)... , Oct. 2, 2014   West Pharmaceutical ... global leader in innovative solutions for injectable drug administration, ... operations to include a new site in ... packaging components for insulin injector cartridges and other high-value ... pharmaceutical and biotech customers. Once operational, this new site ...
(Date:10/1/2014)... Oct. 1, 2014 The Cardinal ... Interested parties can learn about the company,s ... is supporting the health care continuum by ... Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... and the chief executive officer,s letter to ...
Breaking Medicine Technology:Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2
... 2011  TransTech Medical Solutions ( http://www.transtechmedical.com ), today announced ... for Transcription Services in the 2011 Top ... report.  TransTech has previously been ranked #3 in ... the highest overall performance score and 100% of the ...
... 2011  Today, the Consumer Healthcare Products Association (CHPA), announced Tammy ... Five Moms campaign to raise awareness of teen ... two teenage boys and a high school math teacher from ... dangers of substance abuse. Millions of Americans ...
Cached Medicine Technology:TransTech Medical Solutions Ranked #1 by KLAS for 2011 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:10/2/2014)... (PRWEB) October 02, 2014 USARAD ... teleradiology and telemedicine solutions provider including its SecondOpinions.com® ... Backhaus have joined its Executive Team as President ... , Brent Backhaus, USARAD’s new President and COO, ... years of progressively responsible experience in commercial-, medical- ...
(Date:10/2/2014)... Social-Engineer, Inc. the leader in security testing and ... a complimentary webinar on Friday, October 31, at 1:00PM ... of the annual Social-Engineer Capture the Flag (SECTF) competition ... explore how to maximize security and employee performance to ... the webinar go to: Free Webinar Registration . ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3
... - Promotes Commercial Products at Major Cardiology Conferences - - ... - Achieves Efficiencies and Conserves Cash by Consolidating R&D ... ... Neovasc Inc. (TSXV: NVC), a,new specialty vascular device company, today reported on ...
... A very difficult-to-treat child leukemia may benefit from the ... launches the cancer but could potentially be reversed ... The study, led by researchers at Children,s Hospital Boston ... in the November 4 issue of Cancer Cell ...
... Rhode Island Hospital researchers have identified genetic proteins, also ... the microscopic level that can signal a precancerous condition ... who are likely to progress to esophageal cancer. This ... journal Clinical Cancer Research . , Barrett,s esophagus ...
... DUBLIN, Calif., Nov 3 SuperGen, Inc. (Nasdaq:,SUPG), ... development,of novel cancer therapies, today announced that James ... scheduled to present at the,Rodman & Renshaw 10th ... the New York Palace Hotel., SuperGen,s presentation ...
... Global Awards Ceremony Featuring Performances by Grammy Award ... Country Music Star Kenny Rogers, OAK BROOK, ... hosted its 24th Annual Awards of Excellence,celebration on ... who have made outstanding contributions to improve the ...
... CONCORD, Mass., Nov. 3 The Melanoma,Foundation of ... to its fall symposium: "Updates in Melanoma Treatment",presented ... Melanoma Program at Dana,Farber Cancer Institute. A portion ... "Immunotherapy: A Panel Presentation," which includes a panel ...
Cached Medicine News:Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 2Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 3Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 4Health News:Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options 5Health News:Tackling a hard-to-treat childhood cancer by targeting epigenetic changes 2Health News:New research finds markers for esophageal cancer before it develops 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 2Health News:Ronald McDonald House Charities(R) Awards of Excellence Honors Peter and Virginia Ueberroth, Dr. Catherine D. Deangelis and Lionel Whitehead 3
IVUS console...
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
VasoSeal ES is a extravascular arterial sealing. It utilizes a unique temporary arterial locator system which provides an easier and surer method of locating the femoral artery....
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
Medicine Products: